Robin Katie Kelley

1.9k total citations · 1 hit paper
20 papers, 1.3k citations indexed

About

Robin Katie Kelley is a scholar working on Oncology, Hepatology and Surgery. According to data from OpenAlex, Robin Katie Kelley has authored 20 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Hepatology and 6 papers in Surgery. Recurrent topics in Robin Katie Kelley's work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). Robin Katie Kelley is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). Robin Katie Kelley collaborates with scholars based in United States, Taiwan and Spain. Robin Katie Kelley's co-authors include Do‐Youn Oh, Juan W. Valle, Andrew X. Zhu, Bruno Nervi, Rachna T. Shroff, Tanios Bekaii‐Saab, Vincent A. Miller, Hyunseon C. Kang, Daniel H. Ahn and Funda Meric‐Bernstam and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Robin Katie Kelley

20 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biliary tract cancer

2021 594 citations Juan W. Valle, Robin Katie Kelley et al. The Lancet profile →

Peers

Countries citing papers authored by Robin Katie Kelley

Since Specialization

Citations

This map shows the geographic impact of Robin Katie Kelley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Katie Kelley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Katie Kelley more than expected).

Fields of papers citing papers by Robin Katie Kelley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Katie Kelley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Katie Kelley. The network helps show where Robin Katie Kelley may publish in the future.

Co-authorship network of co-authors of Robin Katie Kelley

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Katie Kelley. A scholar is included among the top collaborators of Robin Katie Kelley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Katie Kelley. Robin Katie Kelley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies 2023 ·Hepatology ·Neil Mehta, Robin Katie Kelley, Francis Y. Yao	9
2	New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma 2023 ·Drugs ·John D. Gordan, Bridget P. Keenan, (unknown), Mark Yarchoan, Robin Katie Kelley	9
3	Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures 2022 ·JCO Precision Oncology ·Kabir Mody, (unknown), (unknown), Nilofer S. Azad, Daniel J. Zabransky, Marina Baretti, Rachna T. Shroff, Robin Katie Kelley, (unknown), Adam J. Hockenberry, Denise Lau, Gregory B. Lesinski, Mark Yarchoan	41
4	Biliary tract cancer breakdown → 2021 ·The Lancet ·Juan W. Valle, Robin Katie Kelley, Bruno Nervi, Do‐Youn Oh, Andrew X. Zhu	594
5	Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic 2020 ·Clinical Gastroenterology and Hepatology ·Neil Mehta, Neehar D. Parikh, Robin Katie Kelley, Bilal Hameed, Amit G. Singal	21
6	A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies 2016 ·Breast Cancer Research and Treatment ·A. Jo Chien, (unknown), Craig Fancourt, Emmett V. Schmidt, Mark M. Moasser, Hope S. Rugo, Michelle Melisko, Andrew H. Ko, Robin Katie Kelley, W. Michael Korn, Laura J. Esserman, Laura van’t Veer, Christina Yau, Denise M. Wolf, Pamela N. Münster	28
7	Biliary cancer: Utility of next‐generation sequencing for clinical management 2016 ·Cancer ·Milind Javle, Tanios Bekaii‐Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C. Kang, Daniel V.T. Catenacci, Siraj M. Ali, Sunil Krishnan, Daniel H. Ahn, Andrea Grace Bocobo, Mingxin Zuo, Ahmed O. Kaseb, Vincent A. Miller, Philip J. Stephens, Funda Meric‐Bernstam, Rachna T. Shroff, Jeffrey S. Ross	289
8	Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer. 2013 ·Journal of Clinical Oncology ·A. Jo Chien, Thach‐Giao Truong, Michelle Melisko, Mark M. Moasser, Robin Katie Kelley, Michael Korn, Andrew H. Ko, (unknown), (unknown), Jennifer A. Grabowsky, Mark Jesus M. Magbanua, Hope S. Rugo, Pamela N. Münster	3
9	Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. 2013 ·PubMed ·Celina Ang, Robin Katie Kelley, Michael A. Choti, David Cosgrove, Joanne F. Chou, David S. Klimstra, Michael Torbenson, Linda D. Ferrell, Timothy M. Pawlik, Yuman Fong, Eileen M. O’Reilly, Jennifer Ma, Joseph McGuire, (unknown), A. Clark Griffin, Francesco Stipa, Marinela Capanu, Ronald P. DeMatteo, Alan P. Venook, Ghassan K. Abou‐Alfa	78
10	Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors. 2013 ·Journal of Clinical Oncology ·Andréa Varga, Monica Mita, (unknown), John Nemunaitis, Timothy F. Cloughesy, Paul S. Mischel, Johanna C. Bendell, Kent C. Shih, Luis Paz‐Ares, Amit Mahipal, Jean‐Pierre Delord, Robin Katie Kelley, Jean‐Charles Soria, Lilly Wong, Shuichan Xu, (unknown), Xiaoling Wu, Rajesh Chopra, Kristen Hege, Pamela N. Münster	14
11	Impact of the Recurrence Score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers. 2013 ·Journal of Clinical Oncology ·Robin Katie Kelley, Margarita Lopatin, Jimmy J. Hwang, Michael Crager, (unknown), (unknown), Ashley King, Calvin Chao, Mark Lee, Alan P. Venook	1
12	Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib. 2013 ·Journal of Clinical Oncology ·Andrew H. Ko, Margaret A. Tempero, Tanios Bekaii‐Saab, Peter Kühn, (unknown), (unknown), Sanaa Tahiri, Robin Katie Kelley, Elizabeth Dito, (unknown), (unknown), Olga K. Mirzoeva, Christina Wu, Alan P. Venook, W. Michael Korn	18
13	Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC). 2013 ·Journal of Clinical Oncology ·Sandrine Faivre, Armando Santoro, Robin Katie Kelley, Philippe Merle, Ed Gane, Jean‐Yves Douillard, Dirk Waldschmidt, Mary F. Mulcahy, Charlotte Costentin, Beatriz Mínguez, (unknown), Ivelina Gueorguieva, Ann Cleverly, D. Desaiah, Michael Lahn, (unknown), Karim A. Benhadji, Éric Raymond, Gianluigi Giannelli	6
14	A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies. 2013 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Solmaz Sahebjam, Robin Katie Kelley, Anthony W. Tolcher, Albiruni R. Abdul Razak, Amita Patnaik, Philippe L. Bédard, (unknown), Lieve Adriaens, Carrie Brownstein, Israel Lowy, Bo Gao, (unknown), Pamela A. Trail, Lillian L. Siu	1
15	Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. 2012 ·Journal of Clinical Oncology ·Kent C. Shih, Johanna C. Bendell, (unknown), Suzanne F. Jones, Robin Katie Kelley, Jeffrey R. Infante, Michael Korn, Kristen Hege, Rajesh Chopra, Shuichan Xu, Lilly Wong, Yong Liu, Deborah S. Mortensen, Pamela N. Münster	14
16	Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT). 2012 ·Journal of Clinical Oncology ·Allen Lee Cohn, Robin Katie Kelley, Tsai‐Shen Yang, Wu‐Chou Su, Chris Verslype, David A. Ramies, (unknown), Xiaodong Shen, Eric Van Cutsem	24
17	Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) with pharmacokinetic (PK) and biomarker correlates. 2012 ·Journal of Clinical Oncology ·Robin Katie Kelley, Halla Nimeiri, Pamela N. Münster, Mary F. Mulcahy, Maxwell T. Vergo, (unknown), (unknown), Benjamin M. Yeh, Andrew H. Ko, W. Michael Korn, Jimmy J. Hwang, Madelyn Luttgen, Peter Kühn, Yong Huang, Al B. Benson, Alan P. Venook	3
18	A phase II study to evaluate the safety and efficacy of RAD001 plus erlotinib in patients with well-differentiated neuroendocrine tumors (NET). 2012 ·Journal of Clinical Oncology ·Emily K. Bergsland, (unknown), (unknown), Margaret A. Tempero, W. Michael Korn, Robin Katie Kelley, Thomas Weber, (unknown), Jimmy J. Hwang, Eric K. Nakakura, Alan P. Venook	6
19	A phase Ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (Hh) inhibitor, in pts with advanced pancreatic cancer (PDAC). 2012 ·Journal of Clinical Oncology ·Andrew H. Ko, Noelle K. LoConte, Emily Kantoff, Robert W. Ross, Elizabeth Trehu, Margaret A. Tempero, Robin Katie Kelley, Alan P. Venook, Timothy Wu, Hedy L. Kindler	11
20	Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). 2012 ·Journal of Clinical Oncology ·Chris Verslype, Allen Lee Cohn, Robin Katie Kelley, Tsai‐Shen Yang, Wu‐Chou Su, David A. Ramies, (unknown), Xiaodong Shen, Eric Van Cutsem	92

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact